BOPI 07 BR/2023 REPERTOIRE NUMERIQUE 14 Fig. 1 Fig. 2 Consulter le mémoire ________________________________________ (11) 21036 (51) A61K 31/53 (2018.01); A61P 5/14 (2018.01); C07D 401/14 (2018.01); C07D 403/12 (2018.01) ; C07D 403/14 (2018.01) (21) 1202100500 - PCT/US2020/031904 (22) 07/05/2020 (30) US n° 62/845.252 du 08/05/2019; US n° 62/944,052 du 05/12/2019; US n° 63/005,661 du 06/04/2020 (54) Modulators of Thr-ß and methods of use thereof. (72) VANDYCK, Koen (BE); RABOISSON, Pierre, Jean-Marie, Bernard (BE); DEVAL, Jerome (US) et MCGOWAN, David (BE) (73) ALIGOS THERAPEUTICS, INC., 1 Corporate Drive, 2nd Floor, SOUTH SAN FRANCISCO, California 94080 (US) (74) SPOOR & FISHER Inc. NGWAFOR & PARTNERS Sarl, The House of Gideon, Golf/Bastos Quarters, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) Disclosed herein are compounds of Formula (I) TL-La-CR-HD or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, lIb, IlIa, Illb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substitucnts are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds. Formula (I) Formula IIa, lIb, IlIa, Illb, IIIc, or IIId; Formula IV; Formula V or VI;
RkJQdWJsaXNoZXIy MTM1NDc3MA==